Dechra in the news

Dechra launched Laverdia (verdinexor tablets), the first and only FDA-approved oral treatment for dogs diagnosed with lymphoma.

Dechra launched Laverdia tablets, the first FDA-approved oral treatment for canine lymphoma, providing an at-home alternative to traditional chemotherapy.

Dechra launched an FDA-approved oral treatment, Laverdia, for canine lymphoma that can be given at home.

Dechra introduced Laverdia® (verdinexor tablets), the first and only FDA-approved oral medication for treating lymphoma in dogs, offering an at-home option for pet owners.

Dechra launches Domidine™, a globally trusted equine sedative and analgesic, in the U.S. market, offering veterinarians a cost-effective and proven treatment option.

Dechra introduced Domidine, a generic detomidine, in the U.S. as a cost-effective sedative and analgesic for horses undergoing minor procedures.

Dechra introduced Domidine™, a globally trusted equine sedative and analgesic, to the U.S. market, offering veterinarians a cost-effective and proven option for minor surgical and diagnostic procedures in horses.

Dechra launched Domidine, a trusted equine sedative and analgesic, in the U.S. market, providing a cost-effective and proven option for veterinarians.

Dechra announced its otitis externa treatment, Canaural, is back in stock in a new, recyclable bottle.

Dechra announced its otitis externa treatment, Canaural, is back in stock in a new, recyclable bottle with an improved applicator.

Dechra Pharmaceuticals is undergoing a transitional phase after its £4.5 billion acquisition by EQT in early 2024.

Dechra Pharmaceuticals, a pharmaceutical company, had 2,803 employees globally in March 2026, with workforce growth slowing and job postings declining.

Dechra opened its global headquarters in Boston and invested $60,000 in local animal-assisted therapy and community programs.

Dechra opened its global headquarters in Boston with a $60,000 community investment, focusing on animal-assisted therapy and community engagement.

New and updated renal diets for dogs and cats focus on palatability, gut health, and high Omega-3 levels to manage chronic kidney disease.

Dechra is distributing $80,000 in charitable grants to 24 animal welfare and therapy nonprofits across the United States.

Dechra is moving its global headquarters from England to Boston to tap into the local life sciences ecosystem following its acquisition of Invetx.

Dechra is donating $80,000 to 24 U.S. nonprofits, including equine therapy and senior dog rescue groups, through its annual employee-led giving initiative.

Nearly $80,000 was donated to 24 U.S. charities through an employee-led initiative focused on animal welfare and human-animal bonds.

Dechra is legally defending its patent for an injectable cat and dog vomiting treatment against a revocation attempt by Krka.